Ticker >

Neuland Laboratories share price

Neuland Laboratories Ltd.

NSE: NEULANDLAB BSE: 524558 SECTOR: Pharmaceuticals & Drugs  76k   249   24

7000.00
-3.15 (-0.04%)
BSE: 23 Feb 04:01 PM

Price Summary

Today's High

₹ 7341.95

Today's Low

₹ 6876.8

52 Week High

₹ 7341.95

52 Week Low

₹ 1544.75

FinStar

Ownership Below Par
Stock price may face volatility due to ownership structure.
ValuationFair
The stock’s market price justifies its intrinsic value.
EfficiencyOptimal
The company could improve upon its asset employment.
FinancialsVery Stable
The company possesses stable growth history and manageable debt.
*It is just an analytical rating of the company and not an investment advice.

Company Essentials

Market Cap

8980.92 Cr.

Enterprise Value

9043.79 Cr.

No. of Shares

1.28 Cr.

P/E

28.38

P/B

7.44

Face Value

₹ 10

Div. Yield

0.14 %

Book Value (TTM)

₹  940.81

CASH

58.65 Cr.

DEBT

121.51 Cr.

Promoter Holding

32.8 %

EPS (TTM)

₹  246.69

Sales Growth

25.25%

ROE

17.9 %

ROCE

20.99%

Profit Growth

156.75 %

* Total debt includes long term borrowing, short term borrowing plus current maturities of long-term borrowing
* Ratios are based on latest Audited Financial Result.

Your Added Ratios

Please login to Add & View your own added ratios.

Login

Price Chart 1d 1w 1m 3m 6m 1Yr 3Yr 5Yr

 

Volume Chart 1d 1w 1m 3m 6m 1Yr 3Yr 5Yr

* Prices are based on daily market changes.
* The chart is based on the standalone earnings of the company. * Negative values and values more than 1000x in PE chart is considered 0.

Peer Comparison

View Full Peer Comparison
* The Peers list includes companies operating in the same industry and having comparable market cap.

 Group Companies

Track the companies of Group.

Ratios

Sales Growth

1 Year25.25%
3 Year16.02%
5 Year17.7%

Profit Growth

1 Year156.75%
3 Year117.38%
5 Year69.07%

ROE%

1 Year17.9%
3 Year12.19%
5 Year8.46%

ROCE %

1 Year20.99%
3 Year14.42%
5 Year11.01%

Debt/Equity

0.123

Price to Cash Flow

37.65

Interest Cover Ratio

17.4703329838444

CFO/PAT (5 Yr. Avg.)

1.81266421021267

Share Holding Pattern

Promoter Pledging %

Date Promoter % Pledge %
Dec 2023 32.8 0
Sep 2023 35.97 0
Jun 2023 36.03 0
Mar 2023 36.14 0
Dec 2022 36.14 0
Investors List
* Figures given above are % of equity capital

 Strengths

  • The company has shown a good profit growth of 117.378848209329% for the Past 3 years.
  • The company has shown a good revenue growth of 16.0220962137978% for the Past 3 years.
  • The company has significantly decreased its debt by 109.4362 Cr.
  • Company has a healthy Interest coverage ratio of 17.4703329838444.
  • Company’s PEG ratio is 0.181030555181949.
  • The company has an efficient Cash Conversion Cycle of 60.0080692582113 days.
  • The company has a good cash flow management; CFO/PAT stands at 1.81266421021267.

 Limitations

 Looks like the company does not have any serious limitations.

Quarterly Result (All Figures in Cr.)

PARTICULARS Dec 2022 Mar 2023 Jun 2023 Sep 2023 Dec 2023
Net Sales 269.25 407.07 362.99 417.75 392.83
Total Expenditure 215.31 287.36 265.73 280.45 272.26
Operating Profit 53.94 119.72 97.27 137.3 120.56
Other Income 0.93 8.06 2.04 3.05 2.1
Interest 2.75 4.29 2.21 4.43 3.74
Depreciation 13.34 13.47 13.59 14.51 15.14
Exceptional Items 0 0 0 0 0
Profit Before Tax 38.8 110.02 83.5 121.41 103.78
Tax 8.36 25.51 21.28 32.34 23.08
Profit After Tax 30.44 84.51 62.22 89.07 80.7
Adjusted EPS (Rs) 23.59 65.51 48.23 69.04 62.56

Profit & Loss (All Figures in Cr. Adjusted EPS in Rs.)

PARTICULARS Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023
Net Sales 666.83 762.71 936.91 951.08 1191.2
Total Expenditure 608.96 661.25 790.47 808.88 919.89
Operating Profit 57.87 101.46 146.44 142.19 271.31
Other Income 3.49 3.89 16.09 2.08 9.75
Interest 15.66 21.57 17.9 13.49 13.07
Depreciation 25.86 31.28 39.68 49.04 52.78
Exceptional Items 0 0 0 0 0
Profit Before Tax 19.84 52.5 104.96 81.74 215.21
Tax 3.69 36.62 24.67 18.21 52.09
Net Profit 16.14 15.88 80.29 63.53 163.12
Adjusted EPS (Rs.) 12.58 12.38 62.58 49.52 127.14

Balance Sheet (All Figures are in Crores.)

Particulars Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023
Equity and Liabilities
Share Capital 12.9 12.9 12.9 12.9 12.9
Total Reserves 682.68 692.64 768.98 822.67 975.46
Borrowings 60.72 77.37 88.13 104.25 74.25
Other N/C liabilities 42.41 84.83 80.54 74.17 70.98
Current liabilities 331.19 361.99 372.96 368.13 445.75
Total Liabilities 1129.9 1229.74 1323.52 1382.12 1579.34
Assets
Net Block 511.67 622.75 696.92 747.7 738.19
Capital WIP 104.47 23.75 17.25 20.46 40.57
Intangible WIP 0 0 0 0 0
Investments 0.56 0.52 0.6 0.66 0.68
Loans & Advances 30.45 35.78 41.66 14.4 20.21
Other N/C Assets 29.81 33.11 18.91 19.66 19.34
Current Assets 452.93 513.83 548.18 579.25 760.34
Total Assets 1129.9 1229.74 1323.52 1382.12 1579.34
* Other Non-current Liabilities include Net deferred Liabilities

Cash Flows (All Figures are in Crores.)

PARTICULARS Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023
Profit from operations 19.84 52.5 104.96 81.74 215.21
Adjustment 38.93 58.14 40.17 66.18 76.06
Changes in Assets & Liabilities 15.92 -49.3 49.34 -66.99 -9.17
Tax Paid -5.09 -4.7 -5.19 -20.53 -43.57
Operating Cash Flow 69.6 56.63 189.28 60.41 238.53
Investing Cash Flow -77.22 -48.68 -84.42 -95.53 -61.5
Financing Cash Flow 11.98 -5.48 -113.66 37.72 -135.8
Net Cash Flow 4.36 2.47 -8.8 2.6 41.24

Corporate Actions

Investors Details

PARTICULARS Dec 2022% Mar 2023% Jun 2023% Sep 2023% Dec 2023%
promoters 36.14 36.14 36.03 35.97 32.80
davuluri rohini niveditha... 0.67 0.67 0.67 0.67 0.67
davuluri saharsh rao - - 1.98 2.24 2.24
davuluri sucheth rao 2.63 2.63 - 2.63 2.63
davuluri vijaya rao 4.78 4.78 4.78 4.78 4.78
gannabathula uma bala 0.05 0.05 0.05 0.05 0.05
gannabathula veeravenkata... 0.21 0.21 0.20 0.19 0.18
gannabathula venkata kris... 0.33 0.33 0.33 0.30 0.30
ramamohan rao davuluri 24.97 24.97 24.97 24.71 21.59
usha rani reddy chevalla 0.53 0.53 0.43 0.40 0.36
sucheth rao davuluri - - 2.63 - -
d saharsh rao 1.98 1.98 - - -
PARTICULARS Dec 2022% Mar 2023% Jun 2023% Sep 2023% Dec 2023%
investors 63.86 63.86 63.97 64.03 67.20
investor education and pr... - - - - 0.37
kedia securities private ... 1.01 1.17 1.25 1.25 1.25
malabar india fund limite... 9.95 9.95 9.95 9.95 9.95
malabar value fund 3.65 3.65 2.98 2.69 1.63
matthews india fund 3.81 4.06 4.07 4.07 3.53
mukul mahavir agrawal 3.12 3.12 3.29 3.12 3.12
icg q limited 2.04 2.04 1.69 1.33 -
investor education and pr... 0.35 0.35 0.35 0.35 -
quant mutual fund - quant... - - 1.57 1.50 -
siddharth iyer - - 1.21 1.24 -

Annual Reports

Ratings & Research Reports

Company Presentations

Company News

Neuland Laboratories - Quaterly Results8 Feb 2024, 5:00PM Neuland Laboratories - Quaterly Results8 Feb 2024, 5:00PM Neuland Laboratories - Quaterly Results8 Feb 2024, 5:00PM Neuland Laboratories informs about transcript of earnings call13 Nov 2023, 2:34PM Neuland Laboratories - Quaterly Results7 Nov 2023, 2:38PM Neuland Laboratories - Quaterly Results7 Nov 2023, 2:38PM Neuland Laboratories informs about loss of share certificate(s)20 Oct 2023, 11:23AM Neuland Laboratories - Quaterly Results3 Aug 2023, 3:02PM Neuland Laboratories - Quaterly Results3 Aug 2023, 3:02PM Neuland Laboratories - Quaterly Results3 Aug 2023, 3:02PM Neuland Laboratories informs about newspaper advertisement20 Jun 2023, 11:16AM Neuland Laboratories informs about newspaper publication7 Jun 2023, 4:53PM Neuland Laboratories informs about analyst meet29 May 2023, 4:19PM USFDA completes inspection at Unit 3 manufacturing facility of Neuland Laboratories27 May 2023, 4:40PM Neuland Laboratories - Quaterly Results11 May 2023, 2:02PM Neuland Laboratories - Quaterly Results11 May 2023, 2:02PM Neuland Laboratories - Quaterly Results11 May 2023, 2:02PM Neuland Laboratories submits analyst meet intimation4 May 2023, 4:58PM Neuland Laboratories informs about disclosure 18 Feb 2023, 2:37PM Neuland Laboratories informs about newspaper advertisement14 Feb 2023, 12:02PM Neuland Laboratories - Quaterly Results13 Feb 2023, 5:54PM Neuland Laboratories - Quaterly Results13 Feb 2023, 5:54PM Neuland Laboratories informs about analyst meet2 Feb 2023, 2:53PM Neuland Laboratories informs about voting result of the remote e-voting and scrutinizer’s report23 Dec 2022, 4:25PM Neuland Laboratories informs about issuance of letter of confirmation13 Dec 2022, 10:31AM Neuland Laboratories gets nod to transfer Telangana property to various parties24 Nov 2022, 11:59AM Neuland Laboratories informs about newspaper publication23 Nov 2022, 4:40PM Neuland Laboratories informs about audio recordings of earnings call 11 Nov 2022, 12:54PM Neuland Laboratories - Quaterly Results10 Nov 2022, 6:15PM Neuland Laboratories - Quaterly Results10 Nov 2022, 6:15PM Neuland Laboratories informs about newspaper publication4 Aug 2022, 3:00PM Neuland Laboratories - Quaterly Results3 Aug 2022, 1:45PM Neuland Laboratories - Quaterly Results3 Aug 2022, 1:45PM Neuland Laboratories - Quaterly Results3 Aug 2022, 1:45PM Neuland Laboratories informs about annual report8 Jul 2022, 12:18PM Neuland Laboratories informs about newspaper publication22 Jun 2022, 4:47PM Neuland Laboratories informs about AGM 17 Jun 2022, 12:18PM Neuland Laboratories - Quaterly Results10 May 2022, 4:48PM Neuland Laboratories - Quaterly Results10 May 2022, 4:48PM Neuland Laboratories - Quaterly Results10 May 2022, 4:48PM Neuland Laboratories informs about earnings call details5 May 2022, 3:01PM Neuland Laboratories informs about change in name of share transfer agent 17 Mar 2022, 4:49PM Neuland Laboratories informs about newspaper publication17 Mar 2022, 4:44PM Neuland Laboratories informs about newspaper publication14 Mar 2022, 1:14PM Neuland Laboratories informs about newspaper publication14 Mar 2022, 10:53AM Neuland Laboratories - Quaterly Results1 Feb 2022, 2:35PM Neuland Laboratories - Quaterly Results1 Feb 2022, 2:35PM Neuland Laboratories - Quaterly Results1 Feb 2022, 2:35PM Neuland Laboratories informs about demise of independent director10 Dec 2021, 2:53PM Neuland Laboratories informs about earnings call25 Oct 2021, 1:01PM

Neuland Laboratories Stock Price Analysis and Quick Research Report. Is Neuland Laboratories an attractive stock to invest in?

 

The Indian healthcare sector is expected to reach US$ 372 billion by 2022, driven by rising incomes, greater health awareness, lifestyle diseases and increasing access to insurance. Healthcare has become one of India’s largest sectors - both in terms of revenue and employment.

Healthcare comprises hospitals, medical devices, clinical trials, outsourcing, telemedicine, medical tourism, health insurance, and medical equipment. The structure of the healthcare delivery system in India consists of three broad segments: Primary care, Secondary care, and Tertiary care.

  • Primary care is the first point of contact between the population and the healthcare service providers. For example, Sub-center (SC), Primary Health Centre (PHC) and Community Health Centre (CHC) which is more relevant to rural areas (PHC’s).
  • Secondary care providers inpatient as well as outpatient medical services and includes simple surgical procedures. For example, District level & Mid-sized hospitals.
  • Tertiary care is the third level of the healthcare delivery system in the country. These hospitals are specialized consultative healthcare infrastructure. For example, Single specialty and Multi-specialty hospitals.

While healthcare services are offered by the public as well as private sectors, in urban as well as rural areas, generally people prefer private hospitals over public hospitals for treatment of diseases, illness, and sickness. So, let’s look into Neuland Laboratories and its performance over the period of time.

  • Operating cash flow ratio: It measures the adequacy of a company’s cash generated from operating activities to pay off short-term financial obligations. Neuland Laboratories cash from the operating activity was Rs 238.5321 Cr.
     
  • Financial Strength: Health care organizations usually have high debt loads and low equity capital in their balance sheet. So, Debt to Equity ratio is important to analyze the company’s sustainability. Neuland Laboratories has a Debt to Equity ratio of 0.123 , which is a strong indication for the company.
     
  • EPS growth: Investors should ensure the EPS figure is growing faster than revenue numbers because it indicates company management is increasing the efficiency with which it runs the company. In Neuland Laboratories , the EPS growth was 156.745584594445 % which is good for the company.
     
  • Operating profit margin: It determines a company's potential earnings. It assesses how well-managed a company with respect to its basic overhead costs and other operating expenses, Neuland Laboratories has OPM of 22.7760372331048 % which is a good sign for profitability.
     
  • ROE: Neuland Laboratories have a average ROE of 17.9043312185806 %. ROE is an important financial parameter for hospitals & health care companies because they expand and grow rapidly. Therefore, ROE measures how efficiently a shareholder's fund is used for generating profits.
     
  • Share Price: - The current share price of Neuland Laboratories is Rs 7001.8. One can use valuation calculators of ticker to know if Neuland Laboratories share price is undervalued or overvalued.
Last Updated on:
Brief about Neuland Laboratories

Neuland Laboratories Ltd. Financials: Check Share Price, Balance Sheet, Annual Report, Quarterly Results, Shareholding, Company Profile and News for Company Analysis

Neuland Laboratories Ltd. is a renowned pharmaceutical company that specializes in the manufacture and supply of Active Pharmaceutical Ingredients (APIs) and intermediates. With a rich heritage spanning over three decades, Neuland has emerged as a trusted name in the global pharmaceutical industry.

Neuland Laboratories Ltd. - Share Price

Stay updated with the latest Neuland Laboratories Ltd. share price on our website. Our pre-built screening tools enable you to track the performance of Neuland's stock and monitor any fluctuations in the share price.

Neuland Laboratories Ltd. - Balance Sheet

Access Neuland Laboratories Ltd.'s balance sheet on our website. Our premium features allow you to perform fair value calculations using tools such as DCF Analysis, BVPS Analysis, Earnings Multiple Approach, and DuPont Analysis. These analytical tools provide insights into the financial health and stability of the company.

Neuland Laboratories Ltd. - Annual Report

Downloadable annual reports of Neuland Laboratories Ltd. are available on our website. These reports offer a comprehensive overview of the company's performance, achievements, and future plans. Analyzing the annual report can assist long-term stock investors in making informed decisions.

Neuland Laboratories Ltd. - Dividend

Stay informed about Neuland Laboratories Ltd.'s dividend payouts on our website. Dividends are a significant consideration for long-term investors, and our platform provides detailed information on the company's dividend history and payout ratios.

Neuland Laboratories Ltd. - Quarterly Result

Monitor the quarterly financial performance of Neuland Laboratories Ltd. by accessing the latest results on our website. Use our pre-built screening tools to analyze the company's financial statements and track key metrics. These insights can guide long-term investors in assessing the company's growth trajectory.

Neuland Laboratories Ltd. - Stock Price

Neuland Laboratories Ltd.'s stock price plays a crucial role in investment decisions. Stay up-to-date with the current stock price and historical trends on our website. Our price charts enable long-term investors to analyze patterns and identify potential buying or selling opportunities.

Neuland Laboratories Ltd. - Price Chart

Visualize Neuland Laboratories Ltd.'s stock price trends through our interactive price charts. These charts are designed to assist long-term investors in identifying patterns, trends, and potential entry or exit points.

Neuland Laboratories Ltd. - News

Access the latest news and updates about Neuland Laboratories Ltd. on our website. Stay informed about the company's developments, collaborations, regulatory approvals, and other significant events that may impact its stock performance.

Neuland Laboratories Ltd. - Concall Transcripts

Download the concall transcripts of Neuland Laboratories Ltd. from our website. Concall transcripts provide insights into management discussions, future plans, and strategic decisions. Analyzing these transcripts can aid long-term investors in understanding the company's outlook and prospects.

Neuland Laboratories Ltd. - Investor Presentations

Explore the investor presentations of Neuland Laboratories Ltd. on our website. These presentations provide a comprehensive overview of the company's operations, financial performance, and growth strategies. Reviewing these presentations can be valuable for long-term investors seeking in-depth insights.

Neuland Laboratories Ltd. - Promoters

Neuland Laboratories Ltd. is backed by a strong team of promoters who bring extensive expertise and industry knowledge to the company. The promoters' vision and strategic direction play a pivotal role in shaping Neuland's growth and success.

Neuland Laboratories Ltd. - Shareholders

Stay informed about Neuland Laboratories Ltd.'s shareholders on our website. Understanding the company's ownership structure can provide insights into the level of institutional investment and the overall market sentiment towards the stock.

At our website, we strive to provide comprehensive stock analysis and valuable tools to assist long-term investors in making informed decisions. Take advantage of our pre-built screening tools, downloadable reports, and premium features to enhance your investment research process. Happy investing!

Read More
X